Ceralasertib
Small molecule
Evidence outlook · registrational
Topline reported 2025-12-22
Its supporting mid-stage studies have completed. The sponsor reported topline results on 2025-12-22 (LATIFY Phase III did not meet primary endpoint of overall survival). The announcement is listed under Regulatory events.
Development in Non-Small Cell Lung Cancer stopped (2025-12-22) as a strategic decision by the sponsor. Development continues in another indication. Source
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
LATIFY NCT05450692 · Advanced or Metastatic Non-Small Cell Lung Cancer This was a randomized, phase 3 trial with an active comparator (docetaxel) and a large sample size (594 patients), and it used a hard clinical endpoint (overall survival). However, the study was open-label with no blinding, and per outside reporting the combination therapy did not meet statistical significance for improving overall survival versus docetaxel, so despite the strong design elements this is evidence of an unclear/negative effect rather than a demonstrated benefit. Registry: NCT05450692 | 3 | Overall Survival (OS) (Every 3 months (± 1 week) following objective progression of disease (PD) or treatment discontinuation (up to three years)) 2025-10-06 | LATIFY (NCT05450692), primary endpoint overall survival: ceralasertib + durvalumab did not reach statistical significance vs docetaxel | Partial signal | link ↗ |
View 2 more trials
CLEAR NCT06732401 · Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8 Registry: NCT06732401 | 3 | Disease free survival (DFS) (From randomization to the earliest event defined as the first recurrence of non-small cell lung cancer (NSCLC), any new lung cancer or death, up to 10 years) 2028-06-30 | In progress: results expected 30 Jun 2028 | not yet graded | link ↗ |
NCT02664935 NCT02664935 · Non-Small Cell Lung Cancer, Carcinoma, Squamous Cell, Adenocarcinoma Patients in this arm were not randomized against a comparison group; they were assigned to the ceralasertib-plus-durvalumab arm based on their tumor's molecular profile and treated openly, with outcomes tracked only within that single group. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. Registry: NCT02664935 | 2 | Objective response (OR) (From baseline until disease progression, assessed up to 18 months.); Progression-free survival time (PFS) (From date of commencement of trial treatment to date of CT scan when progressive disease first recorded or date of death without previously recorded progression, assessed up to 18 months.); Durable clinical benefit (DCB) (From baseline until the first scan after 24 weeks showing the patient free of disease progression.) 2023-11-29 | National Lung Matrix Trial (NCT02664935) cohorts J1 (RAS-mutant, n=19) and NAJ (non-actionable-RAS, n=14) of ceralasertib+durvalumab post-checkpoint-blockade NSCLC: DCB rate 39.7% / ORR 13.1% (J1); DCB rate 30.5% / ORR 4.5% (NAJ). | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2 (30)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (15)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
(12 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Ceralasertib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
December 2026 (2)
What to watch
What to watch
2027 (5)
January 2027 (1)
What to watch
March 2027 (1)
What to watch
December 2027 (3)
What to watch
What to watch
What to watch
2028 (4)
March 2028 (1)
What to watch
June 2028 (2)
What to watch
What to watch
December 2028 (1)
What to watch
2031 (1)
February 2031 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent